Subscribe to RSS
DOI: 10.1055/s-0035-1548868
Renin and Aldosterone Measurements in the Management of Arterial Hypertension
Publication History
received 23 July 2014
accepted 12 March 2015
Publication Date:
08 May 2015 (online)
![](https://www.thieme-connect.de/media/hmr/201506/lookinside/thumbnails/2014-07-0229_10-1055-s-0035-1548868-1.jpg)
Abstract
Renin-angiotensin-aldosterone system (RAAS) is recognized as the main regulatory system of hemodynamics in man, and its derangements have a key role in the development and maintenance of arterial hypertension. Classification of the hypertensive states according to different patterns of renin and aldosterone levels (“RAAS profiling”) allows the diagnosis of specific forms of secondary hypertension and may identify distinct hemodynamic subsets in essential hypertension. In this review, we summarize the application of RAAS profiling for the diagnostic assessment of hypertensive patients and discuss how the pathophysiological framework provided by RAAS profiling may guide therapeutic decision-making, especially in the context of uncontrolled hypertension not responding to multi-therapy.
-
References
- 1 Basso N, Terragno NA. History About the Discovery of the Renin-Angiotensin System. Hypertension 2001; 38: 1246-1249
- 2 Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90: 607-673
- 3 Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803
- 4 Weir MR, Dzau VJ. The Renin-Angiotensin-Aldosterone System: A Specific Target for Hypertension Management. Am J Hypertens 1999; 12: 205S-213S
- 5 Takahashi H. Upregulation of the Renin-Angiotensin-Aldosterone-Ouabain System in the Brain Is the Core Mechanism in the Genesis of All Types of Hypertension. Int J Hypertens 2012; 242786
- 6 Gavras H, Brunner HB, Vaughan ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 1973; 180: 1369-1371
- 7 Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274
- 8 Luetscher JA, Boyers DG, Cuthbertson JG, McMahon DF. A model of the human circulation. Regulation by autonomic nervous system and renin-angiotensin system, and influence of blood volume on cardiac output and blood pressure. Circ Res 1973; 32: 84-98
- 9 Brunner HR, Sealey JE, Laragh JH. Renin subgroups in essential hypertension. Further analysis of their pathophysiological and epidemiological characteristics. Circ Res 1973; 32: 99-105
- 10 Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7
- 11 Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449
- 12 Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104
- 13 Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24: 1181-1186
- 14 Tomaschitz A, Pilz S, Ritz E, Morganti A, Grammer T, Amrein K, Boehm BO, März W. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011; 32: 2642-2649
- 15 Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350: 1734-1737
- 16 Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf) 2007; 67: 324-334
- 17 Verhovez A, Mulatero P, Bertello C, Saglio E, Viola A, Tosello F, Rabbia F, Veglio F. Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Press Cardiovasc Prev 2008; 15: 1-5
- 18 Spence JD. Stepped care for hypertension is dead, but what will replace it?. CMAJ 1989; 140: 1133-1136
- 19 Spence JD. Government guidelines for treatment of hypertension. Am J Hypertens 1995; 8: 541
- 20 Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005; 112: 1362-1374
- 21 Song AL, Zeng ZP, Tong AL, Lu L, Chen S, Li M, Fu CL, Wang YH, Sun ML. Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension. (Article in Chinese) Zhonghua Nei Ke Za Zhi 2012; 51: 294-298
- 22 Bernini M, Bacca A, Casto G, Carli V, Cupisti A, Carrara D, Farnesi I, Barsotti G, Naccarato AG, Bernini G. A case of pheochromocytoma presenting as secondary hyperaldosteronism, hyperparathyroidism, diabetes and proteinuric renal disease. Nephrol Dial Transplant 2011; 26: 1104-1107
- 23 Laragh JH. Oral contraceptives – induced hypertension – nine years later. Am J Obstet Gynecol 1976; 126: 141-147
- 24 McVicar M, Carman C, Chandra M, Abbi RJ, Teichberg S, Kahn E. Hypertension secondary to renin-secreting juxtaglomerular cell tumor: case report and review of 38 cases. Pediatr Nephrol 1993; 7: 404-412
- 25 Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80: 633-644
- 26 Rossi GP, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin GP, Ganten D, Pessina AC. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci (Lond) 1997; 93: 435-443
- 27 Lenz T, Kia T, Rupprecht G, Schulte KL, Geiger H. Captopril test: time over?. J Hum Hypertens 1999; 13: 431-435
- 28 Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556
- 29 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202
- 30 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902
- 31 Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 2005; 16: 108-113
- 32 Sealey JE, Gerten JN, Ledingham JG, Laragh JH. Inhibition of renin by heparin. J Clin Endocrinol Metab 1967; 27: 699-705
- 33 Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88: 2384-2392
- 34 Cicala MV, Mantero F. Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology 2010; 92: 44-49
- 35 Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-123
- 36 Warnock DG. Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Int 1998; 53: 18-24
- 37 Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends Endocrinol Metab 2001; 12: 104-111
- 38 Stratakis CA, Karl M, Schulte HM, Chrousos GP. Glucocorticosteroid resistance in humans. Elucidation of the molecular mechanisms and implications for pathophysiology. Ann N Y Acad Sci 1994; 746: 362-376
- 39 Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56: 222-229
- 40 Takeda Y, Yoneda T, Demura M, Furukawa K, Koshida H, Miyamori I, Mabuchi H. Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency. Clin Endocrinol (Oxf) 2001; 54: 751-758
- 41 Hadchouel J, Delaloy C, Fauré S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J Am Soc Nephrol 2006; 17: 208-217
- 42 Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482: 98-102
- 43 Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary aldosteronism and Gordon syndrome. Endocrinol Metab Clin North Am 2011; 40: 343-368
- 44 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Endocrine Society . Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
- 45 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – a review of the current literature. Horm Metab Res 2012; 44: 157-162
- 46 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
- 47 Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833
- 48 Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998; 280: 1168-1172
- 49 Bühler FR, Laragh JH, Baer L, Vaughan Jr ED, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287: 1209-1214
- 50 Adlin EV, Marks AD, Channick BJ. Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med 1972; 130: 855-858
- 51 Bühler FR, Burkart F, Lütold BE, Küng M, Marbet G, Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol 1975; 36: 653-669
- 52 Stumpe KO, Overlack O. Diuretics, beta-blockers or both as treatment for essential hypertension. Br J Clin Pharmacol 1979; 7: 189S-197S
- 53 Veterans Administration Co-operative Study Group On Antihypertensive Agents . Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14: 97S-101S
- 54 Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers JR, Zemel MB, Curry C, Schoenberger J, Wright JT, Kirkendall W, Conradi EC, Jenkins P, McLean B, Massie B, Berenson G, Flamenbaum W. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-1713
- 55 Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramierz EA, Henderson WG. for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921
- 56 Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-2013
- 57 Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20: 771-777
- 58 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
- 59 Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, Collier D, Cruickshank JK, Sever PS, Feder G. ASCOT . Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 2010; 23: 1023-1030
- 60 Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997; 315: 154-159
- 61 Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom S, Williams B. Executive Committee, British Hypertension Society. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81-86
- 62 Vaughan Jr ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol 1973; 32: 523-532
- 63 Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan Jr ED. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-652
- 64 Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens 2011; 24: 1164-1180
- 65 Sealey JE, Parra D, Rosenstein R, Laragh JH. “Effective” plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55: e16
- 66 Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertensionand heart failure. Hypertension 1983; 5: III36-III42
- 67 Woods JW, Pittman AW, Pulliam CC, Werk Jr. EE, Waider W, Allen CA. Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone. N Engl J Med 1976; 294: 1137-1143
- 68 Pedersen EB, Kornerup HJ. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy. Eur J Clin Pharmacol 1977; 12: 93-96
- 69 Nilsson OR, Karlberg BE, Ohlsson O, Thulin T, Tolagen K. Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. Acta Med Scand 1979; 206: 303-308
- 70 Wyndham RN, Gimenez L, Walker WG, Whelton PK, Russell RP. Influence of renin levels on the treatment of essential hypertension with thiazide diuretics. Arch Intern Med 1987; 147: 1021-1025
- 71 Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 1998; 12: 189-194
- 72 Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21: 10-13
- 73 Minami J, Ohno E, Furukata S, Ishimitsu T, Matsuoka H. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension. J Hum Hypertens 2009; 23: 683-686
- 74 Chrysant SG, Danisa K, Kem DC, Dillard BL, Smith WJ, Frohlich ED. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979; 1: 136-141
- 75 Schwartz GL, Bailey K, Chapman AB, Boerwinkle E, Turner ST. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens 2013; 26: 957-964
- 76 Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23: 1014-1022
- 77 Suonsyrjä T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Donner K, Strandberg T, Tikkanen I, Tilvis R, Pentikäinen PJ, Kontula K, Hiltunen TP. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. J Hypertens 2008; 26: 1250-1256
- 78 Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo Jr JL. Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity. Cardiovasc Drugs Ther 2012; 26: 145-155
- 79 Leotta G, Rabbia F, Testa E, Totaro S, Abram S, Milan A, Mulatero P, Veglio F. Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study. Blood Press 2010; 19: 218-224
- 80 Egan BM, Basile JN, Rehman SU, Davis PB, Grob 3rd CH, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792-801
- 81 Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894-896
- 82 Smith SM, Campbell JD. Cost-Effectiveness of Renin-Guided Treatment of Hypertension. Am J Hypertens 2013; 26: 1303-1310
- 83 Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
- 84 James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith Jr SC, Svetkey LP, Taler SJ, Townsend RR, Wright Jr JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
- 85 Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. British Hypertension Society . Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185
- 86 Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-2141
- 87 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201-207
- 88 ONTARGET Investigators . Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
- 89 National Institute for Health and Clinical Excellence – National Clinical Guideline Centre. Clinical Guideline 127. Hypertension – The clinical management of primary hypertension in adults. August 2011. Available at www.nice.org.uk/guidance/CG127 (accessed online on 24th, March 2014)
- 90 Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group . Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374-384
- 91 Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23: 1031-1037